BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Selecta Biosciences, Inc. 

480 Arsenal Street
Building One
Watertown  Massachusetts  02472  U.S.A.
Phone: 617-923-1400 Fax: 617-924-3454


SEARCH JOBS










 Company News
3SBio Inc. (SSRX) Exclusively Licenses Pegsiticase (Uricase PEG-20) To Selecta Biosciences, Inc. To Develop Drug Candidate To Treat Gout 6/18/2014 9:20:48 AM
Selecta Biosciences, Inc. Accelerates Immune Tolerance Therapeutics And Announces New Product Candidate, SEL-212, For Refractory And Tophaceous Gout 6/17/2014 12:56:44 PM
Selecta Biosciences, Inc. Enters Into Exclusive License Agreement With 3SBio Inc. (SSRX) To Develop Drug Candidate To Treat Gout 6/17/2014 11:29:08 AM
Selecta Biosciences, Inc. To Accelerate Program For Novel Dual Action Vaccine For Malaria 6/17/2014 10:11:42 AM
Selecta Biosciences, Inc. Announces Allowance Of The First In A Series Of Patents On The Induction Of Antigen-Specific Immune Tolerance Using Selecta’s Novel Immunotherapies 12/9/2013 9:15:55 AM
Selecta Biosciences, Inc. Announces Successful Pre-Clinical Study Of SEL-201 As An Antigen-Specific Immune Tolerance Treatment For Patients Receiving Factor VIII Therapy 12/9/2013 9:12:04 AM
Selecta Biosciences, Inc. Distinguished as World Economic Forum Technology Pioneer 2014 8/27/2013 10:17:34 AM
Sanofi (France) (SAN.PA) Deal Could Net Selecta Biosciences, Inc. $900 Million 11/28/2012 6:42:44 AM
Selecta Biosciences, Inc. Receives 2012 Edison Award’s Gold Medal for Best Pharmaceutical Product Innovation 5/9/2012 10:27:33 AM
Selecta Biosciences, Inc. Initiates Phase 1 Clinical Study of SEL-068, a First-in-Class Synthetic Nicotine Vaccine for Smoking Cessation and Relapse Prevention 11/21/2011 8:36:09 AM
12